Founded in San Diego, OrPro Therapeutics is a pre-clinical stage biopharmaceutical company focused on developing innovative inhaled non-systemic drugs. Their core mission is to create safe, well-tolerated, and effective treatments for cystic fibrosis (CF) and other serious obstructive pulmonary diseases. The company's primary product is the Theradux® biologic drug platform, designed to address chronic infection, inflammation, and obstructive mucus in the lungs and other epithelial surfaces.
OrPro Therapeutics has attracted notable attention from key figures in the biopharmaceutical industry and investors committed to advancing treatments for pulmonary diseases. Their significant achievements include the development of a promising drug platform that targets the underlying causes of CF and other obstructive lung conditions. The company's work has the potential to significantly improve the quality of life for patients suffering from these debilitating diseases, marking a substantial impact in the field of respiratory health.
